Aptevo Therapeutics Net Worth
Aptevo Therapeutics Net Worth Breakdown | APVO |
Aptevo Therapeutics Net Worth Analysis
Aptevo Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Aptevo Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Aptevo Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Aptevo Therapeutics' net worth analysis. One common approach is to calculate Aptevo Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Aptevo Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Aptevo Therapeutics' net worth. This approach calculates the present value of Aptevo Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Aptevo Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Aptevo Therapeutics' net worth. This involves comparing Aptevo Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Aptevo Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Aptevo Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aptevo Therapeutics' net worth research are outlined below:
| Aptevo Therapeutics generated a negative expected return over the last 90 days | |
| Aptevo Therapeutics has high historical volatility and very poor performance | |
| Aptevo Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (24.13 M) with loss before overhead, payroll, taxes, and interest of (302 K). | |
| Aptevo Therapeutics currently holds about 29.43 M in cash with (23.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: APVO Stock Earnings Aptevo Therapeutics Beats EPS for Q2 2024 - MSN |
Aptevo Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aptevo Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aptevo Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Aptevo Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aptevo Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aptevo Therapeutics backward and forwards among themselves. Aptevo Therapeutics' institutional investor refers to the entity that pools money to purchase Aptevo Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Bank Of America Corp | 2024-12-31 | 4.0 | |
| Truvestments Capital Llc | 2024-09-30 | 2.0 | |
| Wells Fargo & Co | 2024-12-31 | 0.0 | |
| Jane Street Group Llc | 2024-12-31 | 0.0 | |
| Northern Trust Investments N A | 2024-12-31 | 0.0 | |
| Two Sigma Investments Llc | 2024-12-31 | 0.0 | |
| Sabby Management Llc | 2024-09-30 | 0.0 | |
| Hudson Bay Capital Management Lp | 2024-12-31 | 0.0 | |
| Baader Bank Inc | 2024-09-30 | 0.0 | |
| Citadel Advisors Llc | 2024-09-30 | 111.6 K | |
| Virtu Financial Llc | 2024-12-31 | 21.6 K |
Follow Aptevo Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.57 M.Market Cap |
|
Project Aptevo Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.55) | (1.47) | |
| Return On Capital Employed | (2.62) | (2.75) | |
| Return On Assets | (1.55) | (1.47) | |
| Return On Equity | (5.07) | (5.33) |
When accessing Aptevo Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Aptevo Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aptevo Therapeutics' profitability and make more informed investment decisions.
Evaluate Aptevo Therapeutics' management efficiency
Aptevo Therapeutics has return on total asset (ROA) of (0.7606) % which means that it has lost $0.7606 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8428) %, meaning that it created substantial loss on money invested by shareholders. Aptevo Therapeutics' management efficiency ratios could be used to measure how well Aptevo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of March 2025, Return On Tangible Assets is likely to grow to -1.47. In addition to that, Return On Capital Employed is likely to drop to -2.75. At this time, Aptevo Therapeutics' Net Tangible Assets are very stable compared to the past year. As of the 2nd of March 2025, Other Current Assets is likely to grow to about 2.9 M, while Total Assets are likely to drop about 14.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.68 | 15.85 | |
| Tangible Book Value Per Share | 16.68 | 15.85 | |
| Enterprise Value Over EBITDA | 0.12 | 0.12 | |
| Price Book Value Ratio | 0.26 | 0.25 | |
| Enterprise Value Multiple | 0.12 | 0.12 | |
| Price Fair Value | 0.26 | 0.25 | |
| Enterprise Value | 81 M | 76.9 M |
The leadership approach at Aptevo Therapeutics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aptevo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aptevo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aptevo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aptevo Therapeutics Corporate Filings
8K | 14th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify | |
| 20th of December 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Aptevo Therapeutics Earnings per Share Projection vs Actual
Aptevo Therapeutics Corporate Executives
Elected by the shareholders, the Aptevo Therapeutics' board of directors comprises two types of representatives: Aptevo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptevo. The board's role is to monitor Aptevo Therapeutics' management team and ensure that shareholders' interests are well served. Aptevo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptevo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daphne Taylor | Senior CFO | Profile | |
| Daphne CPA | Senior CFO | Profile | |
| Jeffrey CA | Executive COO | Profile |
Already Invested in Aptevo Therapeutics?
The danger of trading Aptevo Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aptevo Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aptevo Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aptevo Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.